Case Report: Dramatic metabolic improvement with tirzepatide in a patient with acquired partial lipodystrophy following hematopoietic stem cell transplantation - Takeaways - MDSpire

Case Report: Dramatic metabolic improvement with tirzepatide in a patient with acquired partial lipodystrophy following hematopoietic stem cell transplantation

  • By

  • Yuri Tanaka

  • Hiroaki Ueno

  • Hirotake Sawada

  • Ayaka Konagata

  • Taisuke Uchida

  • Yudai Uehira

  • Fumiko Kogo

  • Akari Sekishima

  • Hiroshi Moritake

  • Hideki Yamaguchi

  • Kazuya Shimoda

  • June 19, 2026

  • 0 min

Share

  • 1

    Acquired partial lipodystrophy can develop after hematopoietic stem cell transplantation, leading to severe insulin resistance and metabolic complications.

  • 2

    The case study describes a 37-year-old woman with diabetes and fatty liver disease who developed lipodystrophy post-HSCT.

  • 3

    Tirzepatide, a dual GLP-1 and GIP receptor agonist, significantly improved glycemic control in the patient, allowing for insulin therapy discontinuation.

  • 4

    Computed tomography revealed region-specific fat loss in the patient, supporting the diagnosis of acquired partial lipodystrophy.

  • 5

    The patient's high-molecular-weight adiponectin ratio increased after tirzepatide treatment, indicating potential improvement in adipocyte function.

Original Source(s)

Case Report: Dramatic metabolic improvement with tirzepatide in a patient with acquired partial lipodystrophy following hematopoietic stem cell transplantation

  • by Yuri Tanaka, Hiroaki Ueno, Hirotake Sawada, Ayaka Konagata, Taisuke Uchida, Yudai Uehira, Fumiko Kogo, Akari Sekishima, Hiroshi Moritake, Hideki Yamaguchi, Kazuya Shimoda

  • June 19, 2026

Related Content

The predictive value of platelet parameters for the response to initial 131I therapy in patients with differentiated thyroid cancer

Patients’ perspectives on mobile health applications for diabetes self-management: A qualitative study in Malaysia

Exposure to multiple metallic elements and risk of thyroid tumors: insights from elemental profiling, diet, and molecular characteristics plasma levels of metallic elements